Angiogenesis inhibitors in clinical oncology

Update on Cancer Therapeutics

Volumn 1, Issue 4, 2006, Pages 429-434

  George, Daniel J ^a   Moore, Cassandra ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Bevacizumab; Renal cell carcinoma; Sorafenib; Sunitinib; Vascular endothelial growth factor; Vatalinib

Indexed keywords

AG 013736; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AP 23573; AZ 6474; BEVACIZUMAB; CILENGITIDE; CP 673 451; EVEROLIMUS; IMATINIB; MONOCLONAL ANTIBODY LM 609; NEXAVAR; PANCREAS ENZYME; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANGIOGENESIS; ATAXIA; BONE MARROW SUPPRESSION; CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DYSPNEA; EPISTAXIS; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MALAISE; MOUTH PAIN; NAUSEA; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; SKIN DISCOLORATION; STOMATITIS; VOMITING;

EID: 33751324377     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.08.006     Document Type: Review

References (36)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
3. Yang J.C., Haworth S., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
4. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T.N., Hainsworth J., Heim W., et al. N Engl J Med 350 23 (2004) 2335-2342
5. ASCO. Proceedings of the American Society of Clinical Oncology Annual Meeting (2005)
6. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Gore M., Desai A., et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol (2005) [abstract 4544]
7. Escudier B., Szczylik C., Eisen T., Stadler W.M., Schwartz B., Shan M., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol (2005) [abstract 4510]
8. Motzer R.J., Rini B.I., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., et al., The SU11248 Study Group. Phase II trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol (2005) [abstract 4508]
9. Herbst R.S., LoRusso P., Isobe T., and Hurwitz H.I. Angiogenesis pathway inhibitors. Cancer Chemother Biol Response Modif 22 (2005) 225-245
10. Hicklin D.J., and Ellis L.M. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 5 (2005) 1011-1027
11. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 3 7 (2003) 643-651
12. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 S3 (2005) 4-10
13. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 S1 (2004) 2-10
14. Rosen L.S. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 10 (2005) 382-391
15. Ebbinghaus S.W., and Gordon M.S. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematol Oncol Clin N Am 18 (2004) 1143-1159
16. Jain R.K. Normailzation of tumor vasculature: an emerging concept in anti-angiogenic therapy. Science 307 (2005) 58-62
17. Gnarra J.R., Duan D., Weng Y., Humphrey J.S., Chen D.Y., Lee S., et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal cell carcinoma. Biochim Biophys Acta 1242 3 (1996) 201-210
18. Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10 18Pt2 (2004) 6290S-6295S
19. Dagnaes-Hansen F., Rasmussen L.M., Tilton R., Denner L., and Flyvbjerg A. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma. Anticancer Res 23 2B (2003) 1625-1630
20. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrarra N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95 (1995) 1789-1797
21. Lenz H.J. Antiangiogenic agents in cancer therapy. Oncology 19 4Suppl3 (2005) 17-25
22. Potapova O., Laird A., Nannini M., et al. Mechanism of action and biomarker studies of SU11248 a selective inhibitor of split kinase domain receptor tyrosine kinases (including VEGF receptors, PDGF receptors, c-Kit and Flt3). Eur J Cancer 38 s7 (2002) 194
23. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
24. Abrams T.J., Lee L.B., Murray L.J., et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
25. Fiedler W., Serve H., Döhner H., Schwittay M., Ottmann O.G., O'Farrell A.M., et al. A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
26. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
27. Demetri G.D., George S., Heinrich M.C., Fletcher J.A., Fletcher C.D.M., Desai J., et al., The GIST SU11248 Study Group. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol (2003) [abstract 3273]
28. George D., Michaelson D., Oh W.K., Reitsma D., Laurent D., Mietlowski W., et al. Phase I study of PTK787/ZK-222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22 (2003) 385 [abstract 1548]
29. Drevs J., Mross K., Medinger M., Muller M., Laurent D., Reitsma D., et al. Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases. Proc Am Soc Clin Oncol (2003) [abstract 1142]
30. Steward W.P., Thomas A., Morgan B., Wiedenmann B., Bartel C., Vanhoefer U., et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol (2003) [abstract 3556]
31. Trarbach T., Schleucher N., Tewes M., Seeber S., Junker U., Laurent D., et al. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol (2003) [abstract 3605]
32. Hecht J.R., Trarbach T., Jaeger E., Hainsworth J., Wolff R., Lloyd K., et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol (2005) [abstract 3]
33. O'Farrell, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 9 (2003) 3597-3605
34. Wilhelm, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
35. Wood, et al. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular growth factor induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
36. Wickman, et al. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, aG013736 in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Cancer Res 44 (2003) [abstract 3780]